Skip to Content

Gilead Says Lupin Challenges Ranexa patents

From Associated Press (June 11, 2010)

FOSTER CITY, Calif. -- Biotechnology company Gilead Sciences Inc. said Friday its patent on the angina drug Ranexa is being challenged by Lupin Ltd.

Angina is chest pain caused by a lack of blood and oxygen supplied to the heart.

Gilead said Lupin asked the Food and Drug Administration to approve a generic version of the drug. Lupin claims that all 10 patents associated with Ranexa are invalid, unenforceable and, or will not be infringed by Lupin’s generic version.

Gilead said it is currently reviewing the challenge and has 45 days to file a lawsuit. A lawsuit would restrict the FDA from approving Lupin’s generic version for up to 30 months or until a court decision.


Posted: June 2010